3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
71
Neoplasms
10
Skin Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
2
Brain Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Laryngeal Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
cobimetinib
2
spartalizumab
1
pembrolizumab
1
osimertinib
1
glutathione pegylated liposomal doxorubicin
1
entrectinib
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Trastuzumab
1
Taxes
1
Radiosurgery
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
HuMax-IL8
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Vemurafenib
×
Dermatologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled